# Long Term Data Published in JAMA Neurology Demonstrate Sustained Efficacy and Consistent Safety of BRIUMVI in Relapsing Multiple Sclerosis
Canonical URL: https://biopharmsignal.com/news/TGTX/long-term-data-published-in-jama-neurology-demonstrate-sustained-efficacy-and-consistent-safety-of-briumvi-in-relapsing-multiple-sclerosis
Ticker: TGTX
Company: TG Therapeutics
Source: TG Therapeutics
Published: 2026-02-17 12:30 EST
Original Source URL: https://ir.tgtherapeutics.com
## Summary

During year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50 years of patient treatment Overall safety profile of BRIUMVI remained consistent over 5 years of continuous treatment, with no new safety signals emerging with prolonged

## Article Body
During year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50 years of patient treatment Overall safety profile of BRIUMVI remained consistent over 5 years of continuous treatment, with no new safety signals emerging with prolonged
## Recent Company News
- 2026-06-03 11:30 EST — [TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)](https://biopharmsignal.com/news/TGTX/tg-therapeutics-announces-positive-results-from-phase-1-trial-evaluating-subcutaneous-briumvir-ublituximab-xiiy) — Source: TG Therapeutics
- 2026-06-02 11:30 EST — [TG Therapeutics to Participate in the Goldman Sachs 47th Annual Healthcare Conference](https://biopharmsignal.com/news/TGTX/tg-therapeutics-to-participate-in-the-goldman-sachs-47th-annual-healthcare-conference) — Source: TG Therapeutics
- 2026-06-01 11:30 EST — [TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology](https://biopharmsignal.com/news/TGTX/tg-therapeutics-announces-publication-of-post-hoc-data-from-the-phase-3-ultimate-i-and-ii-trials-in-treatment-naive-patients-with-relapsing-forms-of-ms-published-in-frontiers-in-immunology) — Source: TG Therapeutics
- 2026-05-28 11:30 EST — [TG Therapeutics to Participate in the Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/TGTX/tg-therapeutics-to-participate-in-the-jefferies-global-healthcare-conference) — Source: TG Therapeutics
- 2026-05-27 11:30 EST — [TG Therapeutics Announces Positive Topline Results from Phase 3 ENHANCE Trial](https://biopharmsignal.com/news/TGTX/tg-therapeutics-announces-positive-topline-results-from-phase-3-enhance-trial) — Source: TG Therapeutics
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)